Skip to main content
. 2022 Oct 6;13:955925. doi: 10.3389/fphar.2022.955925

FIGURE 5.

FIGURE 5

Forest plot representing a comparison of systemic triplet therapy for improving secondary endpoints compared with ADT plus docetaxel. HR and 95% CrI are represented. (A) Time to castration resistance; (B) time to PSA progression; (C) time to the first symptomatic skeletal event; (D) time to initiation of new antineoplastic therapy.